P2.13-42 Osimertinib Treatment for Patients with EGFR exon 20 Insertion Positive Non-Small-Cell Lung Cancer

B. Van Veggel, A. Van Der Wekken, S. Hashemi, R. Cornelissen, K. Monkhorst, D. Heideman, T. Radonic, E. Schuuring, E. Smit, J. De Langen

Research output: Contribution to journalArticleAcademic

Abstract

Methods: 17 patients with advanced NSCLC harboring an EGFR exon 20 insertion were treated with osimertinib 80 mg once daily, in four institutions in the Netherlands. Data were obtained retrospectively. EGFR mutation status was assessed by next-generation sequencing. Progression free survival (PFS), disease control rate (DCR) and objective response rate (ORR) were assessed using RECIST v1.1.
Original languageEnglish
Pages (from-to)S815
JournalJournal of Thoracic Oncology
Volume13
Issue number10
DOIs
Publication statusPublished - 22 Oct 2018

Cite this